Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | DRD1 | P21728 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | GPR183 | P32249 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | APLNR | P35414 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342509 | 0.91 | HTR2A (0.72) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL25465874 | 0.89 | HTR2A (0.62) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL13191099 | 0.88 | HTR2A (0.65) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL20766423 | 0.88 | HTR2A (0.73) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL3768820 | 0.88 | HTR2A (0.72) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL3959120 | 0.88 | HTR2A (0.72) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL22563294 | 0.88 | HTR2A (0.78) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL20765893 | 0.88 | HTR2A (0.61) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL25571393 | 0.88 | HTR2A (0.80) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 | |
| SCHEMBL25571423 | 0.88 | HTR2A (0.80) | HTR2ACYP1A2HTR2CCYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019040105-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2200610-B1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARM INC (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017015272-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009039461-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039460-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039461-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082342-A1 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082342-A1 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082342-A1 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2006036874-A1 | SALTS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND THEIR PREPARATION | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | HTR2A 185/4885CYP1A2 1127/4885HTR2C 561/4885 |
| US-20090082342-A1 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | HTR3A, HTR5A, HTR1A | HTR2A 11/4885CYP1A2 394/4885HTR2C 12/4885 |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | HTR2A 185/4885CYP1A2 1127/4885HTR2C 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.